NERV news

Latest 1 stories · newest Aug 7, 2026

NERV

Minerva Neurosciences reports Q2 2026 results, update on roluperidone Phase 3 trial

Minerva Neurosciences provided an update on the confirmatory Phase 3 clinical trial of roluperidone for negative symptoms of schizophrenia, expecting topline efficacy data in the second half of 2027. The company announced the addition of experts to its Scientific Advisory Board.

Earnings|Leadership|Other Aug 7, 2026 sentiment 0.00 SEC filing ↗

BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.

The same NERV feed as JSON for your bot or app:

GET https://api.brieftape.com/v1/tickers/NERV/newsSTART FREE